|

AAA617 Clinical Trials

5 actively recruiting trials across 5 locations

Also known as: (177Lu) vipivotide tetraxetan, 177Lu-Lu-PSMA-617, 177Lu-PSMA-617, Lutetium (177Lu) vipivotide tetraxetan, [177Lu]Lu-PSMA-617, Pluvicto +2 more

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 1Phase 4: 1

Top Sponsors

  • Novartis Pharmaceuticals5

Indications

  • Cancer5
  • Oligometastatic Prostate Cancer (OMPC)1
  • Metastatic Castration-resistant Prostate Cancer, mCRPC1
  • Metastatic Castration-resistant Prostate Cancer1
  • Prostate Cancer1

Casa Grande, Arizona1 trial

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Cancer And Blood Spclsts of AZ

Phase 2

Scottsdale, Arizona1 trial

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Mayo Clinic Arizona

Phase 4

Fayetteville, Arkansas1 trial

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Highlands Oncology Group

Phase 3

Los Angeles, California1 trial

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

University of California LA

Phase 1

New York, New York1 trial

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Mount Sinai Hosp Med School

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.